Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Taltz ® (ixekizumab) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Previous Biologic Use in Psoriasis Clinical Trials
The efficacy and safety of ixekizumab was demonstrated regardless of previous treatment with a biologic.1
No overall difference in safety risk was observed between patients with and without previous exposure to biologics in ixekizumab psoriasis clinical trials (see Table 1).2
In ixekizumab phase 3 UNCOVER clinical trials, 26% of all patients had received prior biologic therapy for the treatment of psoriasis. Of these, 15% had received at least 1 anti-TNF alpha agent and 9% had received an anti-IL-12/IL-23.2
No significant treatment-by-previous biologic subgroup interactions were observed when the following TEAEs of special interest were analyzed: injection site reactions, infection-related TEAEs, or allergic reaction/hypersensitivity TEAEs (see Table 1).2
Table 1. Treatment-Emergent Adverse Event Incidence Based on Previous Biologic Subgroup from 12-Week Induction Dosing Period of 3 UNCOVER Clinical Trials2
Previous Biologic Usea |
All TEAE Incidence |
||
|
IXE Q2W (Label Approved Dose) |
IXE Q4W |
PBO |
Yes |
171/315 (54.3%) |
177/311 (56.9%) |
123/257 (47.9%) |
No |
510/852 (59.9%) |
506/850 (59.5%) |
247/534 (46.3%) |
|
Injection Site Reactions Incidenceb |
||
|
IXE Q2W (Label Approved Dose) |
IXE Q4W |
PBO |
Yes |
43/315 (13.7%) |
36/311 (11.6%) |
12/257 (4.7%) |
No |
153/852 (18.0%) |
114/850 (13.4%) |
14/534 (2.6%) |
|
Infection-Related TEAE Incidencec |
||
|
IXE Q2W (Label Approved Dose) |
IXE Q4W |
PBO |
Yes |
79/315 (25.1%) |
85/311 (27.3%) |
61/257 (23.7%) |
No |
236/852 (27.7%) |
233/850 (27.4%) |
120/534 (22.5%) |
|
Allergic Reaction/Hypersensitivity TEAE Incidenced |
||
|
IXE Q2W (Label Approved Dose) |
IXE Q4W |
PBO |
Yes |
11/315 (3.5%) |
9/311 (2.9%) |
5/257 (1.9%) |
No |
30/852 (3.5%) |
37/850 (4.4%) |
12/534 (2.2%) |
Abbreviations:
IXE = Ixekizumab; PBO = Placebo; Q2W = every 2 weeks; Q4W = every 4
weeks; TEAE = treatment-emergent adverse event.
Statistical
Results: There were no statistically significant
treatment-by-previous biologic treatment subgroup interactions for
the analyses listed above.
Please refer to the Taltz summary of product characteristics for the full list of adverse reactions.
a In ixekizumab phase 3 UNCOVER clinical trials, 26% of all patients had received prior biologic therapy for the treatment of psoriasis. Of these, 15% had received at least 1 anti-TNF alpha agent, and 9% had received an anti-IL-12/IL-23.
b The most frequent injection site reactions observed were erythema and pain. These reactions were predominantly mild to moderate in severity and did not lead to discontinuation of ixekizumab.
c The most frequent infections reported were nasopharyngitis, upper respiratory tract infections, and urinary tract infections.
d Most allergic reactions/hypersensitivity events were mild or moderate and did not lead to discontinuation. There were no confirmed cases of ixekizumab-related anaphylaxis events.
The dosing schedule IXEQ4W during the first 12 weeks of treatment (induction phase) is not consistent with the approved dosing schedule for plaque psoriasis in the Taltz summary of product characteristics. Please refer to the Taltz summary of product characteristics for approved dosing. 1
Therapeutic Indication
Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
1. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
IL-17 = interleukin-17
IL-23 = interleukin-23
TEAE = treatment-emergent adverse event
TNF = tumor necrosis factor
Datum fӧr senaste ӧversyn 2020 M01 10